13 recruiting, 4 completed, 4 not yet recruiting, 4 unknown. 19 Phase 1, 11 Phase 2, 1 Early Phase 1, 1 Phase 3.
Follow T-cell Acute Lymphoblastic Leukemia: new trials by email Literature Review of T-cell Acute Lymphoblastic Leukemia trials Research Report on T-cell Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Universal 4SCAR7U Targeting CD7-positive Malignancies Universal CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-08-26 |
| Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2026-12-31 | 2026-08-26 |
| Chidamide Maintenance to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute T-Lymphoblastic Leukemia/Lymphoma Chidamide, Control Group - T-Cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic Lymphoma | Phase 3 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 132 | 2026-08-15 | 2026-08-19 |
| A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma Autologous nano CD5-CAR T Cells - T-Cell Acute Lymphoblastic Leukemia, T-Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 18 | 2026-06-30 | 2026-07-01 |
| Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma Venetoclax, Dexamethasone, Bortezomib - T-cell Acute Lymphoblastic Leukemia, Lymphoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 18 | 2026-06-05 | 2026-08-12 |
| NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL Antigen-specific T cells CAR-T/CTL and DCvac - T-Cell Acute Lymphoblastic Leukemia | Phase 1 | Terminated | Shenzhen Geno-Immune Medical Institute | 10 | 2026-06-01 | 2026-08-24 |
| Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells CD7.CAR/28zeta T Cells - T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma | Phase 1 | Recruiting | Baylor College of Medicine | 27 | 2026-05-12 | 2026-05-18 |
| A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) Decitabine, Venetoclax, Calaspargase pegol-mknl - T-cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 22 | 2025-09-25 | 2026-09-18 |
| A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) WU-CART-007 - T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 2 | Recruiting | Allotera Therapeutics | 125 | 2025-01-31 | 2026-09-28 |
| Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) Dexamethasone, Vincristine, Daunorubicin - T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 100 | 2024-12-27 | 2026-08-10 |
| Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention Azacitidine (AZA) Days 1 - 5, Decitabine (DAC), Venetoclax - T-cell Acute Lymphoblastic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 59 | 2024-10-30 | 2025-05-07 |
| Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells CD5/CD7 CAR-T - T Cell Lymphoma, T Cell Leukemia | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 60 | 2024-07-10 | 2024-11-12 |
| Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies Autologous CD7 CAR T-cell, Prior-HSCT donor-derived CD7 CAR T-cell, New donor-derived CD7 CAR T-cell - T-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | Phase 1 / Phase 2 | Recruiting | Beijing GoBroad Hospital | 80 | 2024-03-22 | 2025-11-26 |
| Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL Daratumumab / Hyaluronidase Injection - T-cell Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Eastern Cooperative Oncology Group | 20 | 2023-05-25 | 2026-09-15 |
| Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma Daratumumab - T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic Lymphoma | Phase 1 | Recruiting | New York Medical College | 30 | 2023-05-22 | 2026-09-11 |
| Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL CD1a-CAR T - T-cell Acute Lymphoblastic Leukemia, Lymphoblastic T-Cell Lymphoma | Phase 1 | Recruiting | OneChain Immunotherapeutics | 20 | 2023-01-31 | 2026-03-11 |
| CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia CD5 CAR-T - T-cell Acute Lymphoblastic Leukemia | Phase 1 | Unknown | Xuanwu Hospital, Beijing | 20 | 2022-10-25 | 2022-10-27 |
| A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007 Genetic: WU-CART-007 - T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma | Enrolling by invitation | Allotera Therapeutics | 44 | 2022-08-22 | 2024-11-20 | |
| Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies anti-CD7 CAR-T cells - T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia | Phase 1 | Completed | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 14 | 2022-05-04 | 2025-06-06 |
| Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients Venetoclax, Azacitidine - T-cell Acute Lymphoblastic Leukemia, Recruiting | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 28 | 2022-04-01 | 2026-03-19 |
Showing 20 of 30. Sign in to see all of them.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (30) · Lymphoma, T-Cell (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Lymphoma (4) · Leukemia (3) · Leukemia, Myeloid, Acute (2) · Leukemia, T-Cell (2) · Hematologic Neoplasms (1) · Immunoblastic Lymphadenopathy (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Prolymphocytic, T-Cell (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, T-Cell, Peripheral (1) · Recurrence (1)
Hematologic Diseases (30) · Hemic and Lymphatic Diseases (30) · Immune System Diseases (30) · Immunoproliferative Disorders (30) · Leukemia, Lymphoid (30) · Lymphatic Diseases (30) · Lymphoproliferative Disorders (30) · Neoplasms (30) · Neoplasms by Histologic Type (30) · Leukemia (27) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (25) · Lymphoma, Non-Hodgkin (5) · Leukemia, Myeloid (2) · Lymphoma (2) · Disease Attributes (1)
venetoclax (5) · Dexamethasone (3) · daratumumab (3) · Azacitidine (2) · Bortezomib (2) · Decitabine (2) · calaspargase pegol (2) · Calcium Dobesilate (1) · Control Groups (1) · Cyclophosphamide (1) · Cytarabine (1) · Dasatinib (1) · Daunorubicin (1) · Hyaluronoglucosaminidase (1) · Hydrocortisone (1)
Allotera Therapeutics (3) · Baylor College of Medicine (3) · Shenzhen Geno-Immune Medical Institute (3) · M.D. Anderson Cancer Center (2) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (2) · iCell Gene Therapeutics (2) · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (1) · Beijing Boren Hospital (1) · Beijing GoBroad Hospital (1) · Eastern Cooperative Oncology Group (1) · Eli Lilly and Company (1) · Essen Biotech (1) · First Affiliated Hospital of Zhejiang University (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · New York Medical College (1)
China (13) · United States (12) · Australia (3) · France (3) · Germany (1) · Israel (1) · Italy (1) · Netherlands (1) · Spain (1) · Sweden (1)
Cherry Thomas, MD (3) · Rayne Rouce, MD (3) · LaQuisa Hill, MD (2) · Allyson Flower, MD (1) · David McCall, MD (1) · Hongyu Zhang (1) · Hongyu Zhang, MD/PhD (1) · Huyong Zheng, MD, PhD (1) · Jing Pan, Master (1) · Miriam B Garcia, DOp (1) · Mitchell Cairo, MD (1) · Piotr Kozlowski, MD (1) · Sanbin Wang, Doctor (1) · Seth E. Karol, MD, MSCI (1)
PMID 33107983, PMID 34274536, PMID 36086817, PMID 36858787, PMID 39149468, PMID 39354195, PMID 40445850, PMID 41619724
2014 (1), P50CA126752 (1), R35CA210084 (1)